Therapy options are limited for men with advanced-stage, metastatic castration-resistant prostate cancer, but a new treatment protocol offers hope. Researchers report on their novel dosing regimen for actinium-225-labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)-positive tumors. The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects.
from Top Health News – ScienceDaily http://bit.ly/2xZc3Gs
from Tumblr http://bit.ly/2xOBYkn
No comments:
Post a Comment